SCHEMBL3535155

SCHEMBL3535155

CN1CCN(c2ccc3[nH]c(-c4n[nH]c5cccc(O)c45)nc3c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 9/20 0.59
FLT1 P17948 3/20 0.59
MAP4K1 Q92918 1/20 0.48
TOP1 P11387 2/20 0.47
TOP2A P11388 2/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CDK2 P24941 3/20 0.47
CDK4 P11802 1/20 0.47
CCNA2 P20248 1/20 0.47
CCND1 P24385 1/20 0.47
CCND3 P30281 1/20 0.47
PRKCZ Q05513 2/20 0.46
KDR P35968 5/20 0.46
PDGFRB P09619 3/20 0.46
FLT3 P36888 1/20 0.46
ACHE P22303 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3536846 0.89 FGFR1 (0.47) FGFR1FLT1MAP4K1ALDH1A1CDK2
SCHEMBL3538010 0.86 FGFR1 (0.57) FGFR1FLT1MAP4K1ALDH1A1SMN1; SMN2
SCHEMBL3539547 0.85 FGFR1 (0.61) FGFR1FLT1MAP4K1TOP1TOP2A
SCHEMBL3542672 0.85 FGFR1 (0.43) FGFR1FLT1MAP4K1CDK2CDK4
SCHEMBL3538752 0.81 FGFR1 (0.64) FGFR1FLT1TOP1TOP2AALDH1A1
SCHEMBL3537178 0.80 CDK2 (0.65) FGFR1FLT1TOP1TOP2AALDH1A1
SCHEMBL5866750 0.80 FGFR1 (0.71) FGFR1FLT1MAP4K1TOP1TOP2A
SCHEMBL3537272 0.80 FGFR1 (0.71) FGFR1FLT1MAP4K1TOP1TOP2A
SCHEMBL3533576 0.80 FGFR1 (0.71) FGFR1FLT1MAP4K1TOP1TOP2A
SCHEMBL31006247 0.80 FGFR1 (0.71) FGFR1FLT1MAP4K1TOP1TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885MAP4K1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.